Antithrombotic and Bleeding Effects of a New Synthetic Direct Thrombin Inhibitor and of Standard Heparin in the Rabbit

Summary

This study reports on (he anticoagulant, antithrombotic and bleeding effects of a new synthetic direct thrombin inhibitor (SDTI) in comparison with standard heparin (SH). The anticoagulant effect was determined with the thrombin clotting time (TCI) and the activated partial thromboplastin time (APTT). SDTI was more potent than SII in prolonging the TCT, but as potent as SH in prolonging the APTT. The antithrombotic effect was determined using a modified Wessler model in the rabbit, either 30 min after a continuous IV infusion of increasing doses or at various times after a single SC injection (20 mg/kg). After continuous IV infusion of 187 μg/kg/h of SDTI and of 60 μg/kg/h of SH, significant thrombus prevention effects were obtained (59 and 57% respectively). Increasing the dose of SDTI up to 3000 μg/kg/h did not significantly impiove the antithrombotic effect. After SC injection, a significant antihrombotic effect was observed for 12 h with SDTI but for more than 24 h with SH. The bleeding effect was studied using the rabbit ear model 15 min after a continuous infusion of 7.5 and 15 mg/kg/h: the amounts of blood loss were dose-dependent and comparable for SDTI and SH. These studies also indicated that SDTI possesses a considerable shorter half-life in comparison with SH. Accordingly, the ex vivoconcentrations generated after continuous IV infusion or SC injection of the same dose were higher for SH than for the SDTI.

Keywords

Thrombin inhibitor - Heparin - Experimental thrombosis

• References

• 1 Okelford PA, Carter CJ, Mitchell L, Hirsh J. Discordance between the anti-Xa activity and the antithrombotic activity of an ultra-low molecular weight heparin fraction. Thromb Res 1982; 28: 401-409
• 2 Walenga M, Fareed J, Petitou M, Samama M, Lormeau JC, Choay J. Intravenous antithrombotic activity of a synthetic heparin pentasaccharide in a human serum-induced stasis thrombosis model. Thromb Res 1986; 43: 243-248
• 3 Buchanan MR, Boneu B, Ofosu FA, Hirsh J. The relative importance of thrombin and factor Xa inhibition to the antithrombotic effects of heparin. Blood 1985; 65: 198-201
• 4 Fernandez F, Van Ryn J, Ofosu FA, Hirsh J, Buchanan MR. The haemorrhagic and antithrombotic effect of dermatan sulphate. Br J Haematol 1986; 64: 309-317
• 5 Hauptmann J, Kaiser B, Markwardt F, Nowak G. Anticoagulant and antithrombotic action of novel specific inhibitors of thrombin. Thromb Haemostas 1980; 43: 118-123
• 6 Hauptmann J, Markwardt F. Studies on the anticoagulant and antithrombotic action of an irreversible thrombin inhibitor. Thromb Res 1980; 20: 347-351
• 7 Tremoli E, Morazzoni G, Maderna P, Colli S, Paoletti R. Studies on the antithrombotic action of BOC-D-PHE-PRO-ARG-H (Giky 14 451). Thromb Res 1981; 23: 549-553
• 8 Kaiser B, Hauptmann J, Weiss A, Markwardt F. Pharmacological characterization of a new highly effective synthetic thrombin inhibitor. Biomed Biochim Acta 1985; 44: 1201-1210
• 9 Regoeczi E. Fibrinogen catabolism: kinetics of catabolism following sudden elevation of the pool with exogenous fibrinogen. Clin Sci 1970; 38: 111-121
• 10 Kaiser B, Markwardt F. Antithrombotic and haemorrhagic effects of synthetic and naturally occurring thrombin inhibitors. Thromb Res 1986; 43: 613-620
• 11 Collen D, Matsuo O, Stassen JM, Kettner C, Shaw E. In vivo studies of a synthetic inhibitor of thrombin. J Lab Clin Med 1982; 99: 77-83
• 12 Markwardt F, Nowak G, Hoffmann J. Comparative studies on thrombin inhibitors in experimental microthrombosis. Thromb Haemostas 1983; 49: 235-237
• 13 Matsuo T, Nakao K, Yamada T, Matsuo O. Effect of a new anticoagulant (MD 805) on platelet activation in the hemodialysis circuit. Thromb Res 1986; 41: 33-41